Screener Summaries Updates Institutions Sign In More Updates › Other Events › HRTX Other Events · Aug 14, 2026
Heron Therapeutics entered into Amendment No. 1 to its Tax Benefit Preservation Plan on August 13, 2026, extending the… HRTX Heron Therapeutics, Inc.
Heron Therapeutics entered into Amendment No. 1 to its Tax Benefit Preservation Plan on August 13, 2026, extending the plan's Final Expiration Date from August 14, 2026, to August 14, 2029. This modification preserves the company's ability to utilize net operating loss carryforwards by adjusting the timeline of its shareholder rights agreement. Heron Therapeutics operates in the biopharmaceutical industry and develops treatments for pain management.
More from Heron Therapeutics, Inc. Heron Therapeutics signs multi-product license deal with Long Grove and Capstone for US rights Sep 29, 2026 Heron Therapeutics reported Q2 2026 net revenue of $37.7 million and ended the quarter with $42.7 million in cash Aug 10, 2026 On June 25, 2026, Heron Therapeutics received notice from Nasdaq that it failed to meet the minimum $1.00 bid price… Jun 25, 2026 At its 2026 Annual Meeting of Stockholders on June 11, 2026, Heron Therapeutics approved several key proposals Jun 16, 2026 Heron Therapeutics announced that a U.S. District Court ruled on June 1, 2026, that its U.S. Patent Nos. 12,115,255… Jun 2, 2026 All content on this site is for informational purposes only and does not constitute financial, investment, legal, or tax advice. Past performance is not indicative of future results. Always consult a qualified financial advisor before making investment decisions.
Financial data is obtained from public filings and third-party providers and is provided “as-is” without any guarantee of accuracy, completeness, or timeliness.
© 2026 go-intrinsic.com. All rights reserved.
